Skip to main content
Premium Trial:

Request an Annual Quote's AncestryDNA Service Exceeds 400,000 Members Genotyped


NEW YORK (GenomeWeb) – announced last week that it has genotyped 400,000 members since launching its array-based autosomal DNA testing service, AncestryDNA, two years ago. The Provo, Utah-based online genealogy company most recently provided an update on the service in February, when it said it had genotyped 300,000 customers to date.

"With that scale and network effect, we've created a product that is really valuable to our existing subscribers while also providing new users a fast and easy way to start learning about their family history," CEO Tim Sullivan said in a statement.

By increasing its database of genotyped members, AncestryDNA is able to deliver on one component of its offering: matching distant relatives. said that it has identified more than 15 million cousin relationships since it rolled out AncestryDNA in May 2012.

AncestryDNA relies on a 700,000-marker Illumina BeadChip to genotype participants. In addition to its matching service, the company also provides customers with a biogeographical ancestry estimate based on 26 global regions.

The company also said that its growing database has enabled AncestryDNA to begin constructing a new genetic graph of the US population. It expects this genetic graph to become a "unique and valuable resource that will become the cornerstone of future product developments and differentiation for AncestryDNA in the market."

Ken Chahine, general manager of AncestryDNA, told BioArray News at the RootsTech conference in February that the firm expects its exponential growth rate to continue.

"I predict that we are at the very early part of the S curve," Chahine said at the time. "I think we are just getting past the early adopters, we are just barely going mainstream, and I don't think we have hit that massive inflection point," he said. "There is no question in my mind, that in a couple years, we could be sitting here talking about doing a million samples a year."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.